Top Clinical Trial Supply Trends of 2024 and How to Meet and Exceed Them, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insights into the top industry trends being seen as it is related to clinical trial supplies Attendees will learn how to strategically meet and exceed these trends. The featured speaker, Tom Gregson, Vice President of Business Development, Myonex, will discuss... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 21, 2024 Category: Pharmaceuticals Tags: TRI Source Type: news
Tharimmune's Oral'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease
Tuesday, Tharimmune Inc THAR completed its Phase 1 clinical trial with TH104, a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene, which easily adheres inside of the mouth on the cheek and biodegrades within minutes. TH104 is designed to avoid the liver’s…#tharimmuneincthar #phase1 #th104 #fda #tharimmune #thar (Source: Reuters: Health)
Source: Reuters: Health - February 20, 2024 Category: Consumer Health News Source Type: news
Peninsula biotech halts 2 clinical trials, stock loses 70% of value
The company, focused on inflammatory diseases such as asthma and eczema, has lost close to a half-billion dollars since it started in 2015. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 20, 2024 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Global Health Institute opens new location off campus
East Syracuse site will be home to institute ’s clinical trials for new vaccines, drug treatments for infectious diseases. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - February 20, 2024 Category: Universities & Medical Training Tags: News Source Type: news
Aycan moves into clinical trials market with Enspectra Health contract
Radiology informatics firm Aycan Medical Systems has moved into the clinical trials market via a contract with Enspectra Health.
Enspectra has used Aycan’s PACS, viewers, and professional services team to prepare DICOM data generated from their Vio system for a clinical trial. Vio visualizes skin cellular structures in real-time, Aycan said. The U.S. Food and Drug Administration (FDA) cleared Vio on January 4. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 20, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Blue Earth highlights early lutetium-177 prostate cancer clinical results
Blue Earth Therapeutics is highlighting early clinical results from a German trial investigating the use of a lutetium-177 (Lu-177)-labeled prostate specific antigen (PSMA) radiopharmaceutical.
A study conducted by researchers from University Hospital Augsburg in Germany used Blue Earth's Lu-177-labeled radiohybrid (rh) prostate-specific membrane antigen (Lu-177 rhPSMA-10.1) and its findings were published in December in the Journal of Nuclear Medicine.
The German team reported that of four patients with metastatic prostate cancer who were assessed for radiologic progression-free survival, two had not progressed at 24 an...
Source: AuntMinnie.com Headlines - February 20, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Antiviral Mechanism and Clinical Benefits of Mouthwash Active Against SARS-CoV-2
Reia, V.C.B., da Fonseca Orcina, B., Vilhena, F.V.et al. Antiviral Mechanism and Clinical Benefits of Mouthwash Active Against SARS-CoV-2.Curr Oral Health Rep (2024). https://doi.org/10.1007/s40496-024-00368-1AbstractPurpose of ReviewWe
aim to review the spectrum of biological mechanisms of mouthwashes
shown to be active against SARS-CoV-2, evidence for efficacy in
reduction of viral load, in vitro and in vivo, and the potential for
clinical benefit in use of mouthwashes in the context of COVID-19.Recent FindingsNumerous
studies have now been performed to establish the antiviral efficacy of
specific mouthwash i...
Source: Dental Technology Blog - February 19, 2024 Category: Dentistry Source Type: news
World Health Organization risk drinking levels among mandated college students: associations with alcohol use, mental health, and academic performance - Reid AE, Cho GY, Carey KB, Witkiewitz K.
OBJECTIVE: World Health Organization (WHO) risk drinking levels (i.e., low, moderate, high, or very high risk) have been used as a drinking reduction endpoint in clinical trials. Yet, prior work has not attempted to quantify reductions in WHO risk levels a... (Source: SafetyLit)
Source: SafetyLit - February 19, 2024 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Groundbreaking Food Allergy Treatment Research to Be Unveiled at 2024 American Academy of Allergy, Asthma & amp; Immunology Annual Meeting
Media Advisory for Late Breaking Symposium at the 2024 AAAAI Annual Meeting MILWAUKEE, Feb. 19, 2024 /PRNewswire-PRWeb/ -- Renowned allergist Dr. Robert A. Wood, MD FAAAAI, will present detailed findings from a Phase 3 clinical trial that will have significant impact in the world of food... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 19, 2024 Category: Pharmaceuticals Tags: TRI Source Type: news
Novel Treatment For Damaged Corneas: Cell Therapy
Cell therapies show promise for treating eye conditions. One approach injects cultured human corneal endothelial cells with a ROCK inhibitor, yielding positive results in small clinical trials. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 17, 2024 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Closing the clinical trials disparity gap
Getting sufficient representation of racial and ethnic minority populations in clinical trials remains a pervasive challenge, despite concerted efforts by researchers and mandates set by funding sources and regulatory agencies. A lack of diversity in research results in continued disparities and poorer health outcomes in underrepresented communities. An article in the January edition of Mayo Clinic Proceedings proposes a wide range of strategies to help researchers improve community engagement with underrepresented racial and ethnic populations and… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 17, 2024 Category: Databases & Libraries Source Type: news
Alnylam stock sinks after last-minute changes in key drug trial
Alnylam Pharmaceuticals Inc. saw its stock price sink to its lowest point in the last year after the Cambridge company announced changes to a Phase 3 clinical trial that's already underway. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 16, 2024 Category: Biotechnology Authors: Hannah Green Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Investor Update - February 16, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Media News - February 16, 2024 Category: Pharmaceuticals Source Type: news
Cochrane Sweden wrongly suspended from social media platform X
Last week, areport co-authored by Cochrane Sweden revealed that the results of hundreds of Nordic clinical trials remain unpublished. The team shared the report on the social media platform X, formerly known as Twitter. Two days later, their account wassuspended from the platform following reports from unknown users. The team are appealing the decision but have had no response so far.Since 2019, Cochrane Sweden have been involved in improving trial transparency,publishing reports and organizinginternational webinars. The latest report found that 475 clinical trials involving 83,903 patients completed during 2016-19 in Denm...
Source: Cochrane News and Events - February 16, 2024 Category: Information Technology Authors: Harry Dayantis Source Type: news
